StockData
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. (LRMR) stock

LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$2.99−0.01 (-0.33%)

Close on Nov 17, 2026Market cap $310.61MP/E –Yield –

Larimar Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Larimar Therapeutics's price to book ratio was 2.2× on Nov 11, 2026, against 2.2× a year earlier. Over the last 5 years it ranged from 0.6× to 6.2×, with a median of 1.9×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.2×−0.1
2025Dec 31, 20252.3×+1.1
2024Dec 31, 20241.2×−0.9
2023Dec 29, 20232.2×+0.6
2022Dec 30, 20221.5×−1.1
2021Dec 31, 20212.7×−0.6
2020Dec 31, 20203.2×−259.2
2019Dec 31, 2019262.4×+241.3
2018Dec 31, 201821.1×+4.0
2017Dec 29, 201717.1×+9.1
2016Dec 30, 20168.0×−2.8
2015Dec 31, 201510.8×−64.7
2014Dec 31, 201475.6×–

More Larimar Therapeutics figures

See a number that looks wrong?